BioAdaptives, Inc. (BDPT)
OTCMKTS
· Delayed Price · Currency is USD
0.0625
+0.0035 (5.93%)
Jul 14, 2025, 3:32 PM EDT
BioAdaptives Revenue
BioAdaptives had revenue of $675.00 in the twelve months ending March 31, 2025, down -98.18% year-over-year. In the year 2024, BioAdaptives had annual revenue of $12.67K, down -55.65%.
Revenue (ttm)
675.00
Revenue Growth
-98.18%
P/S Ratio
837.84
Revenue / Employee
675.00
Employees
1
Market Cap
565.54K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 12.67K | -15.90K | -55.65% |
Dec 31, 2023 | 28.57K | 11.39K | 66.31% |
Dec 31, 2022 | 17.18K | -2.60K | -13.15% |
Dec 31, 2021 | 19.78K | 3.45K | 21.12% |
Dec 31, 2020 | 16.33K | 6.39K | 64.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cordyceps Sunshine Biotech Holdings | 1.25M |
Cuisine Solutions | 80.48M |
Armanino Foods of Distinction | 69.40M |
South Dakota Soybean Processors, LLC | 524.07M |
ESG Inc. | 11.89M |
Pyxus International | 2.48B |
Crimson Wine Group | 71.52M |
Hi-Great Group Holding Company | 69.04K |
BioAdaptives News
- 20 days ago - BioAdaptives Announces National Launch of Pawpa™ Regen - GlobeNewsWire
- 6 weeks ago - BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements - GlobeNewsWire
- 4 months ago - Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial - GlobeNewsWire
- 5 months ago - BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - GlobeNewsWire
- 5 months ago - BioAdaptives Welcomes Mark Frissora, Acclaimed Business Leader, to Its Board of Directors - GlobeNewsWire
- 6 months ago - BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - GlobeNewsWire
- 7 months ago - This Wide Moat ETF Could Be 2025 Star - ETF Trends
- 7 months ago - BioAdaptives, Inc. Launches Xcellara™ Stem Cell Activator – Harnessing Nature for Optimal Health - GlobeNewsWire